{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T03:06:57Z","timestamp":1788923217931,"version":"build-2803163510"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>The efficacy of intrathecal drug delivery (IDD) for cancer-related pain is well established. Cancer therapies are often associated with immunosuppression and increased risk of infection, and the rate of infection after intrathecal drug delivery system (IDDS) implant in cancer patients has been reported as 2.4%\u20136.3%. Our objective is to report on the rate of surgical site infections (SSI) in patients implanted with IDDS for cancer-related pain and to provide a data-driven discussion on the relationship between antineoplastic treatment, leukopenia, and other clinical or demographic characteristics and SSI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>Following local institutional review board approval, we conducted a retrospective chart review of IDDS implants from May 2014 through December 2018. Data collected included demographic data, health status, prophylactic antibiotic administration, surgery duration, presence of leukopenia (white blood cell [WBC] count of &lt;4.0 K\/\u00b5L) or moderate neutropenia (absolute neutrophil count [ANC] of &lt;1000\/\u03bcL) within the 30 days before IDDS implant, and details of antineoplastic treatment or systemic corticosteroid use in the perioperative period. This information was assessed in relation to SSI incidence up to 6 months following implant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>Two hundred seventeen IDDS implants were identified. A majority of patients (79.3%) received \u22651 form of antineoplastic therapy within 30 days before or after implant, and 42.4% received multiple forms of antineoplastic therapy. Therapies included chemotherapy in 46.5%, immunotherapy in 28.6%, systemic steroids in 32.3%, and radiation therapy in 28.1%. One-quarter of patients (25.8%) were leukopenic within 30 days before implant, with 3.2% having moderate neutropenia. There were 2 infectious complications representing an infection rate of 0.9% (95% CI, 0.1%\u20133.3%), with limited shared characteristics between those experiencing SSI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>SSI risk after IDDS placement for cancer pain is low, despite frequent concurrent antineoplastic therapy and leukopenia in the perioperative period. Concomitant cancer therapies should not be a barrier to the implementation of IDD for cancer pain.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1213\/ane.0000000000004639","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T15:48:29Z","timestamp":1580226509000},"page":"280-287","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":22,"title":["The Rate of Infectious Complications After Intrathecal Drug Delivery System Implant for Cancer-Related Pain Is Low Despite Frequent Concurrent Anticancer Treatment or Leukopenia"],"prefix":"10.1213","volume":"131","author":[{"given":"Jill E.","family":"Sindt","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, University of Utah, Salt Lake City, Utah"},{"name":"Huntsman Cancer Institute, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Larsen","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, University of Utah, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Dalley","sequence":"additional","affiliation":[{"name":"University of Utah School of Medicine, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem H.","family":"Collier","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, University of Utah, Salt Lake City, Utah."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane E.","family":"Brogan","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, University of Utah, Salt Lake City, Utah"},{"name":"Huntsman Cancer Institute, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,1,23]]},"reference":[{"key":"R1-20250810","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jpainsymman.2015.12.340","article-title":"Update on prevalence of pain in patients with cancer: systematic review and meta-analysis.","volume":"51","author":"van den Beuken-van Everdingen","year":"2016","journal-title":"J Pain Symptom Manage"},{"key":"R2-20250810","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.1995.03530230056031","article-title":"The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation.","volume":"274","author":"Jadad","year":"1995","journal-title":"JAMA"},{"key":"R3-20250810","first-page":"68","article-title":"Cancer pain management: part II: interventional techniques.","volume":"15","author":"Scott-Warren","year":"2015","journal-title":"BJA Educ"},{"key":"R4-20250810","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/annonc\/mdi156","article-title":"An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM).","volume":"16","author":"Smith","year":"2005","journal-title":"Ann Oncol"},{"key":"R5-20250810","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1093\/pm\/pnw060","article-title":"Intrathecal therapy for cancer-related pain.","volume":"17","author":"Bruel","year":"2016","journal-title":"Pain Med"},{"key":"R6-20250810","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1213\/ANE.0000000000002903","article-title":"Intrathecal drug delivery systems for refractory pancreatic cancer pain: observational Follow-up Study over an 11-year period in a comprehensive cancer center.","volume":"126","author":"Carvajal","year":"2018","journal-title":"Anesth Analg"},{"key":"R7-20250810","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/AAP.0000000000000251","article-title":"Prospective observational study of patient-controlled intrathecal analgesia: impact on cancer-associated symptoms, breakthrough pain control, and patient satisfaction.","volume":"40","author":"Brogan","year":"2015","journal-title":"Reg Anesth Pain Med"},{"key":"R8-20250810","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1213\/ANE.0000000000004276","article-title":"Prospective association of serum opioid levels and clinical outcomes in patients with cancer pain treated with intrathecal opioid therapy.","volume":"130","author":"Brogan","year":"2020","journal-title":"Anesth Analg"},{"key":"R9-20250810","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/ner.12759","article-title":"Retrospective analysis of intrathecal drug delivery: outcomes, efficacy, and risk for cancer-related pain at a high volume academic medical center.","volume":"21","author":"Sayed","year":"2018","journal-title":"Neuromodulation"},{"key":"R10-20250810","first-page":"520","article-title":"Surgical site infections in cancer patients with intrathecal drug delivery devices.","volume":"18","author":"Scanlon","year":"2017","journal-title":"Pain Med"},{"key":"R11-20250810","doi-asserted-by":"crossref","first-page":"251","DOI":"10.36076\/ppj.2013\/16\/251","article-title":"Infectious complications related to intrathecal drug delivery system and spinal cord stimulator system implantations at a comprehensive cancer pain center.","volume":"16","author":"Engle","year":"2013","journal-title":"Pain Physician"},{"key":"R12-20250810","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/ner.12609","article-title":"Spinal cord stimulator implant infection rates and risk factors: a multicenter retrospective study.","volume":"20","author":"Hoelzer","year":"2017","journal-title":"Neuromodulation"},{"key":"R13-20250810","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1533-2500.2010.00407.x","article-title":"Retrospective review of 707 cases of spinal cord stimulation: indications and complications.","volume":"11","author":"Mekhail","year":"2011","journal-title":"Pain Pract"},{"key":"R15-20250810","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s00268-003-7193-3","article-title":"Surgical site infections in breast surgery: case-control study.","volume":"28","author":"Vilar-Compte","year":"2004","journal-title":"World J Surg"},{"key":"R16-20250810","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.wneu.2015.12.068","article-title":"Predictors of surgical site infection following craniotomy for intracranial neoplasms: an analysis of prospectively collected data in the American College of Surgeons National Surgical Quality Improvement Program Database.","volume":"88","author":"McCutcheon","year":"2016","journal-title":"World Neurosurg"},{"key":"R17-20250810","doi-asserted-by":"crossref","first-page":"109","DOI":"10.6004\/jnccn.2008.0012","article-title":"Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice.","volume":"6","author":"Crawford","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"R18-20250810","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1086\/671006","article-title":"Infection related to implantable central venous access devices in cancer patients: epidemiology and risk factors.","volume":"34","author":"Freire","year":"2013","journal-title":"Infect Control Hosp Epidemiol"},{"key":"R19-20250810","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1002\/cncr.25286","article-title":"Severe neutropenia at time of port insertion is not a risk factor for catheter-associated infections in children with acute lymphoblastic leukemia.","volume":"116","author":"Junqueira","year":"2010","journal-title":"Cancer"},{"key":"R20-20250810","doi-asserted-by":"crossref","first-page":"e0148076","DOI":"10.1371\/journal.pone.0148076","article-title":"Adjusted age-adjusted Charlson Comorbidity Index score as a risk measure of perioperative mortality before cancer surgery.","volume":"11","author":"Chang","year":"2016","journal-title":"PLoS One"},{"key":"R22-20250810","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1525-1403.2012.00476.x","article-title":"Polyanalgesic consensus conference 2012: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel.","volume":"15","author":"Deer","year":"2012","journal-title":"Neuromodulation"},{"key":"R23-20250810","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/ner.12579","article-title":"The Polyanalgesic Consensus Conference (PACC): recommendations for intrathecal drug delivery: guidance for improving safety and mitigating risks.","volume":"20","author":"Deer","year":"2017","journal-title":"Neuromodulation"},{"key":"R24-20250810","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/pbc.22286","article-title":"Complications and risk factors of infection in pediatric hemato-oncology patients with totally implantable access ports (TIAPs).","volume":"54","author":"Nam","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"R25-20250810","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1200\/JCO.1999.17.4.1304","article-title":"Hickman catheter-related infections in neutropenic patients: insertion in the operating theater versus insertion in the radiology suite.","volume":"17","author":"Nouwen","year":"1999","journal-title":"J Clin Oncol"},{"key":"R27-20250810","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1002\/cncr.25691","article-title":"Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy.","volume":"117","author":"Lyman","year":"2011","journal-title":"Cancer"},{"key":"R28-20250810","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ygyno.2012.03.015","article-title":"Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer.","volume":"125","author":"Laskey","year":"2012","journal-title":"Gynecol Oncol"},{"key":"R29-20250810","first-page":"483","article-title":"Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study.","volume":"19","author":"Schwenkglenks","year":"2011","journal-title":"Support Care Cancer"},{"key":"R30-20250810","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.ctrv.2013.01.004","article-title":"Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.","volume":"39","author":"Funakoshi","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"R31-20250810","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","article-title":"Toxicities of immunotherapy for the practitioner.","volume":"33","author":"Weber","year":"2015","journal-title":"J Clin Oncol"},{"key":"R32-20250810","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline.","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"R33-20250810","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/ner.12265","article-title":"Infectious complications of intrathecal drug administration systems for spasticity and chronic pain: 145 patients from a tertiary care center.","volume":"18","author":"Malheiro","year":"2015","journal-title":"Neuromodulation"},{"key":"R34-20250810","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/ner.12767","article-title":"Retrospective case series on the treatment of painful diabetic peripheral neuropathy with dorsal root ganglion stimulation.","volume":"21","author":"Eldabe","year":"2018","journal-title":"Neuromodulation"},{"key":"R35-20250810","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/ner.12538","article-title":"The Polyanalgesic Consensus Conference (PACC): recommendations on intrathecal drug infusion systems best practices and guidelines.","volume":"20","author":"Deer","year":"2017","journal-title":"Neuromodulation"},{"key":"R36-20250810","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/ner.12565","article-title":"The Neurostimulation Appropriateness Consensus Committee (NACC) recommendations for infection prevention and management.","volume":"20","author":"Deer","year":"2017","journal-title":"Neuromodulation"}],"container-title":["Anesthesia &amp; Analgesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1213\/ANE.0000000000004639","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:27:37Z","timestamp":1786112857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1213\/ANE.0000000000004639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,23]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1213\/ane.0000000000004639","relation":{},"ISSN":["0003-2999"],"issn-type":[{"value":"0003-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1,23]]}}}